- AuthorisedTherapeutic use (Phase IV)
A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.
This study looks at how people with Parkinson's disease use a device called OraFID and a special app to take their Flexilev medicine. It aims to understand how well they use it and how they feel about it over 12 weeks.
For: Parkinsons DiseaseSweden - AuthorisedTherapeutic confirmatory (Phase III)
Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (DARE-Trial) - A multicenter, randomized, double-blind, placebo-controlled trial with group sequential design
This study is testing a new tablet called DHEA alongside usual antidepressant treatment for people with depression that hasn't improved with other treatments. Researchers want to see if DHEA helps reduce depression symptoms over six weeks and if it's safe to use.
For: Treatment Resistant Depression (TRD)Germany